Cholesterol combo not superior to solo drug

updated 6:11 p.m. ET Jan. 14, 2008

NEWARK, N.J. - Drug developers Merck & Co. and Schering-Plough Corp. on Monday said patients with a predisposition to high cholesterol fared no better when taking their combination cholesterol drug Vytorin than with a high dose of the generic form of Zocor.

Vytorin is a combination of Zetia and Merck's Zocor, which lost patent protection in 2006. The study measured the amount of artery-clogging plaque in three areas.

It focused on a group of 720 patients with a rare condition predisposing them to high cholesterol. The patients were given either Vytorin or a high dose of generic Zocor, known as simvastatin.

In December, a congressional committee requested more information on the study. The results were delayed, the companies maintained, because of the complexity of the data.

The patients in the two-year study had rare condition called heterozygous familial hypercholesterolemia, which the companies said affected about less than 1 percent of the population.

Earlier this month, Merck CEO Richard T. Clark said he expected Vytorin to keep a secure position in the cholesterol drug market and cited several other ongoing studies in addition to this one.

Merck and Schering-Plough are conducting three additional studies, involving more than 20,000 high-risk patients.

Don't miss this on msnbc.com Health   It's no secret! Why we love gossip When you are denied insurance 5 smart snack tips to help you slim down Is my breast cancer upsetting you?  |    Famous survivors At long last, food label law takes effect

MORE FROM HEALTH CARE

Health care Section Front

Couple can sue vaccine company, court says When you are denied health insurance ‘Revisions’ to knee, hip implants on the rise Developing nations lack medical workers 1 in 4 chance McCain may not survive 2nd term Oregon hospital tells grandpa he’s pregnant Nuclear waste piling up at U.S. hospitals Man claims penis amputated without consent On fire in the OR: Hundreds are hurt every year Seniors skip generic drugs if Medicare is paying Health care Section Front   Add Health care headlines to your news reader: